Zoek in de HOVON website
Mogelijk ziet u niet alle beschikbare info op deze pagina, omdat u niet bent ingelogd, of omdat u niet de juiste privileges heeft.
Clinical picture: NHL (Non Hodgkin Lymphoma)
Trial: HOVON 152 DLBCL
2. Patient eligibility criteria
3. Registration (& randomization) of patients
4. Participating parties
5. Participating sites
6. Instruction videos
7. Download documentation / forms
HO 152 newsstudy is in preparation
Patients with high grade B cell lymphoma th at harbor a MYC combined with a BCL2 and/or a BCL6 rearrangement (double-hit or triple-hit high-grade B cell lymphoma, DH/TH HGBL) have a dismal prognosis following standard treatment with R-CHOP. Intensified treatment with DA-EPOCH-R induces higher complete metabolic remission (CMR) rates and prolongs disease free survival (DFS) as compared to R-CHOP and other intensified chemotherapy regimens, but relapses do often occur and improved overall survival (OS) has not been achieved.
Check-point inhibitors like nivolumab show promising results in relapsed Non-Hodgkin lymphoma. We expect to induce deeper remissions with DA-EPOCH-R than with R-CHOP, providing a good platform for immune checkpoint inhibition to consolidate complete remission or to induce remission in minimal residual disease (MRD) positive patients, resulting in better DFS.
Type of study
Prospective Phase II study
Echelon level specification
Limited nr of sites
Type of monitoring for this study
Site evaluation visits
Target number of patients